CTRI/2012/04/002582已完成1 期
Trial of Candidate Live Oral Cholera Vaccine VA 1.4: A Phase I-II Study to Evaluate the Safety and Immunogenicity in Healthy Adults in Kolkata, India
Department of Biotechnology Ministry of Science and Technology Government of India0 个研究点目标入组 88 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Males or non-pregnant females aged 18 years to 60 years who
- •1. The investigator believes will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection).
- •2. Have given written informed consent obtained from the subjects.
- •3. Are healthy as determined by
- •a) Medical history
- •b) Physical examination
- •c) Clinical judgment of the investigator
排除标准
- •1. Having ongoing serious chronic disease
- •2. For females of reproductive age: Pregnancy (or females planning to become pregnant during the study period (as determined by verbal screening)
- •3. Immunocompromising condition or therapy (for corticosteroids this would mean >=0.5 mg/kg/day)as determined through verbal screening and history of recent ARI, diabetes, repeated attacks of diarrhoea
- •4.Diarrhea (3 or more loose/watery stools within a 24-hour period)6 weeks prior to enrollment
- •5. One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months
- •6. One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months
- •7. Intake of any anti-diarrhea medicine in the past week
- •8. Having abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours
- •9. Having any acute disease one week prior to enrollment, with or without fever. Temperature >=38ºC warrants deferral of the vaccination pending recovery of the subject.
- •10. Receiving immunoglobulin or any blood product during the past 3 months
- •11. Receiving antibiotics in past 14 days
- •12. Receiving live or killed enteric vaccine in past 4 weeks
- •13. Receiving killed oral cholera vaccine
- •14. Subject belonging to a population/family at high risk for HIV/AIDS such as migrant workers, commercial vehicle drivers, parenteral drug users, sex workers. Also in case of doubt the subject will be excluded.
研究者
相似试验
已完成
1 期
Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules)Safety of the Oral O1 / O139 Cholera Vaccine (Enteric Capsules)NCT03237663Jiangsu Province Centers for Disease Control and Prevention60
已完成
1 期
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult MenPrevention Harmful EffectsNCT01707537EuBiologics Co.,Ltd20
已完成
4 期
VAXCHORA Pediatric Study to Assess Safety and ImmunogenicityCholera (Disorder)NCT03220737Bavarian Nordic550
已完成
1 期
Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A InfectionSalmonellaNCT01129453University of Maryland, Baltimore51
已完成
2 期
Immunologic Responses to a Live Attenuated Oral Cholera VaccineCholeraNCT03251495Emory University34
